In December 2020, Veraxa Biotech AG was founded in Zurich, Switzerland, to acquire Araxa Biosciences GmbH and Velabs Therapeutics GmbH, both based in Heidelberg, Germany.

Veraxa Biotech AG focuses on the development of antibody-drug conjugates through an innovative click chemistry approach and the microfluidic screening of functional antibodies. The portfolio ranges from early-stage projects to those in the clinical phase. Veraxa Biotech is a spin-off of the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Currently, Veraxa Biotech is concentrating on developing therapeutics for the oncology market, one of the largest markets in the medical field. To expand and further develop its portfolio, Veraxa Biotech collaborates with national and international research institutions and industrial partners.

For more information, please visit: www.veraxa.com